Organisation paid for research Program year 2025 Source: CMS Open Payments

Logan Ophthalmic Research LLC

Neither a doctor nor a teaching hospital

Research payments

$245,414

71 payments

Through program year 2025, Logan Ophthalmic Research LLC is reported as receiving $245,414 in research payments, across 71 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$57,546	11
2024	Research	$59,087	12
2023	Research	$61,219	9
2022	Research	$15,675	6
2021	Research	$14,508	2
2020	Research	$3,115	20
2019	Research	$34,265	11

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $193,527 38 payments
Allergan Inc. $51,888 33 payments

Studies the money was for Research payments · program years 2019–2025

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $104,197 20 payments
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $36,368 27 payments
Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension $27,914 9 payments
1698-302-007 Ph3 Extension Study (M21-489) $17,684 1 payment
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $16,211 1 payment
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $13,500 1 payment
SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $12,589 3 payments
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $5,885 1 payment
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $4,219 1 payment
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $4,161 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.